论文部分内容阅读
目的:研究脑血疏口服液联合依达拉奉对高血压脑出血的治疗效果及对血清白介素-6(IL-6)、IL-1β、基质金属蛋白酶-9(MMP-9)的影响。方法:选取2014年10月至2016年9月我院收治的102例高血压脑出血患者,根据入院顺序分为观察组和对照组,51例每组。对照组使用常规治疗,观察组在此基础上采取脑血疏口服液联合依达拉奉完成治疗。比较两组患者临床疗效,神经功能评分、血肿周围水肿量、血肿量,血清IL-6、IL-1β、MMP-9水平。结果:治疗后,观察组临床总有效率显著高于对照组[94.12%(48/51)比78.43%(40/51)](P<0.05);神经功能评分、血肿量、周围水肿量显著低于对照组[(11.04±1.21)分、(8.65±0.54)m L、(5.87±0.54)m L比(19.87±1.76)分、(13.56±1.23)m L、(9.65±0.92)m L](P<0.05);血清IL-6、IL-1β、MMP-9水平低于对照组[(8.98±0.87)ng/m L、(12.34±1.21)ng/L、(74.21±8.42)ng/L比(11.21±1.02)ng/m L、(23.87±2.37)ng/L、(92.17±9.86)ng/L](P<0.05)。两组患者不良反应的发生率比较差异无统计学意义(P>0.05)。结论:脑血疏口服液联合依达拉奉治疗高血压脑出血的临床疗效明显优于常规治疗,可能与其有效降低患者血清IL-6、IL-1β、MMP-9水平有关。
Objective: To study the therapeutic effect of Naoxuesu oral liquid combined with edaravone on hypertensive intracerebral hemorrhage and its effect on serum levels of interleukin-6 (IL-6), IL-1β and matrix metalloproteinase-9 (MMP-9). Methods: From October 2014 to September 2016, 102 patients with hypertensive intracerebral hemorrhage admitted to our hospital were divided into observation group and control group according to admission sequence, and 51 patients in each group. The control group was treated with conventional therapy. On the basis of this, the observation group took NaoxueShu oral liquid and edaravone to complete the treatment. The clinical efficacy, neurological function score, peripheral edema volume, hematoma volume, serum IL-6, IL-1β and MMP-9 levels were compared between the two groups. Results: After treatment, the total effective rate in the observation group was significantly higher than that in the control group [94.12% (48/51) vs 78.43% (40/51)] (P <0.05); neurological scores, hematoma volume and peripheral edema were significantly Lower than the control group (11.04 ± 1.21), (8.65 ± 0.54) m L, (5.87 ± 0.54) m L vs (19.87 ± 1.76), (13.56 ± 1.23) m L, (9.65 ± 0.92) m L (P <0.05). The levels of IL-6, IL-1β and MMP-9 in serum were significantly lower than those in the control group [(8.98 ± 0.87) ng / m L, (12.34 ± 1.21) ng / L, / L ratio (11.21 ± 1.02) ng / m L, (23.87 ± 2.37) ng / L, (92.17 ± 9.86) ng / L] There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: The clinical curative effect of Naoxuesu oral liquid combined with edaravone on hypertensive intracerebral hemorrhage is obviously better than that of routine treatment, which may be related to the decrease of serum IL-6, IL-1β and MMP-9.